For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of long-lived assets | - | -22,305* | - | 44,611 |
| Research and development | 28,719 | 42,180* | 30,106 | 29,761 |
| Research and development related success payments and contingent consideration | 8,433 | 9,353* | 3,124 | 10,262 |
| General and administrative | 11,462 | 13,357* | 10,285 | 10,341 |
| Total operating expenses | 48,614 | 42,584 | 43,515 | 94,975 |
| Loss from operations | -48,614 | -42,584* | -43,515 | -94,975 |
| Interest income, net | 951 | 1,478* | 1,003 | 577 |
| Other income, net | 453 | 868* | 360 | 598 |
| Net loss | -47,210 | -40,238 | -42,152 | -93,800 |
| Basic EPS | -0.17 | -0.154 | -0.16 | -0.39 |
| Diluted EPS | -0.17 | -0.154 | -0.16 | -0.39 |
| Basic Average Shares | 276,856,000 | 260,799,000 | 260,494,000 | 238,409,000 |
| Diluted Average Shares | 276,856,000 | 260,799,000 | 260,494,000 | 238,409,000 |
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)